Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
8.45
+0.07 (0.77%)
Market open: Aug 12, 2026, 11:16 AM EDT
8.27
-0.12 (-1.43%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
| Name | Position |
|---|---|
| Dr. Anh T. Nguyen M.B.A., M.D. | Chief Medical Officer |
| Mr. Brian Conner | SVP of Quality and Chief Compliance & Risk Officer |
| Mr. John P. Shannon | Chairman & CEO |
| Mr. Kevin McCulloch | President & COO |
| Mr. Steven M. Pieper | Chief Financial Officer |
| Ms. Allison Wey | Senior Vice President of Investor Relations & Corporate Communications |
| Ms. Beth P. Hecht J.D. | Chief Legal Officer & Corporate Secretary |
| Ms. Kendal Korte | Senior Vice President of Human Resources |
| Date | Type | Document |
|---|---|---|
| 2026-08-06 | 8-K | xers-20260806.htm |
| 2026-07-17 | 8-K | xers-20260715.htm |
| 2026-06-30 | 8-K | xers-20260629.htm |
| 2026-06-11 | 8-K | xers-20260610.htm |
| 2026-06-05 | 8-K | xers-20260604.htm |
| 2026-05-07 | 8-K | xers-20260507.htm |
| 2026-05-07 | 10-Q | xers-20260331.htm |
| 2026-04-23 | DEF 14A | xers-20260423.htm |
| 2026-04-23 | ARS | xers2025annualreport.pdf |
| 2026-04-21 | 8-K | xers-20260420.htm |